IL17A and rheumatoid arthritis: The preclinical agent SNX-7081 suppressed RA pathology in animal models by disrupting NF-κB activation and resulting SASP-associated cytokine production (TNF-α, IL-17, IL-6, IL-8), leading to the suppression of joint inflammation (Table 1) (91).